These experiments have firmly established the contribution of one or more toxic properties of mutant SOD1 within glial cells to drive ALS and have motivated the development of SOD1-lowering therapeutic approaches, which are currently being tested in the clinic16–18. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.